bit.bio raises $30 Million led by M&G Investments
bit.bio raises $30 Million led by M&G Investments to focus on tools for the research, drug discovery and cell therapy markets.
bit.bio expand Executive Team with appointment of Przemek Obloj as Chief Financial Officer
Cambridge, UK – bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, announces the appointment of Przemek Obloj as Chief Financial Officer. Mr. Obloj will oversee the company’s financial strategy, including fundraising, and work closely with Founder and CEO, Mark Kotter, and the Executive Team to support continued growth and innovation.
bit.bio chooses Automata as partner for automating a key aspect of its production of iPSC derived human cells
Automation will support bit.bio’s production of its scalable, consistent human cells for research and drug discovery with greater manufacturing capacity and speed than ever.
bit.bio raises $103 million in first close of Series B financing
Today bit.bio announces the first close of its Series B financing of $103 million. The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
bit.bio expands Board of Directors with appointment of entrepreneurs and Nobel Laureate
bit.bio has welcomed three new members to its Board of Directors, who bring their respective experience of turning world class science into new industries and company growth. The new directors will provide important guidance as bit.bio scales their proprietary synthetic biology cell programming technology platform, creating products and solutions based on human cells that can transform healthcare…
bit.bio welcomes Anthony Browne MP to open Cambridge headquarters
South Cambridgeshire MP Anthony Browne has officially opened the labs and office space of Cambridge-based synthetic biology start-up bit.bio.
bit.bio joins forces with maths institute to find the ‘operating system of life’
Cell coding startup bit.bio partrners with science institute on a moonshot mission to create every human cell type for biomedical research and therapy.
Bit Bio secures $41.5 million of funding from top life science investors
Bit Bio, a Cambridge-based synthetic biology company combining data science and biology to code cells for the wellbeing of humanity, has announced the close of a $41.5 million Series A investment, bringing the company’s total funding to $50 million.
Bit Bio’s ‘enter button for the keyboard to the software of life’ nabs the company $41.5 million
Jonathan Shieber of Tech Crunch writes about Bit Bio's technoloigy and its latest funding round.
Sure, Bit Bio got some significant cash for its cell coding work. But it’s the insiders who are backing them that will garner the attention
John Carroll of Endpoints News writes about Bit Bio's recent funding round.